The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection

Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. No statistical methods were used to determine sample size for proteogenomics analyses. Ultimately, sample size was determined by the access and availability of patient samples and patient material, as well as lab capacity. Sample size is sufficient for this proof-of-concept study showing that tumor non-canonical peptides can be identified for every patient.
No data was excluded
Mass spectrometry discovery based studies were replicated at least twice (please see Supplementary Data 1 for detailed information on replicates for MS-based analyses), and were reproducible. Sequencing data has not been replicated due to the significant cost of additional sequencing, which were determined to not bring additional value to the results presented. T cell based assays were replicated at least twice and the data can be reproduced.
Randomization was not applied in these experiments as this was not applicable to our present study. This is due to the fact that it was a proofof-concept exploratory research with a small set of samples. The study was solely based on identifying non-canonical antigens in immunopeptidomics data.
The study was not blinded as this is not applicable/relevant to our current study to identify non-canonical HLAp. This is due to the fact that it was a proof-of-concept exploratory research with a small set of samples. The study was solely based on identifying non-canonical antigens in immunopeptidomics data.
